MSD in den Nachrichten
Spitzenwissenschaft für die Gesundheit
Tamtam hat 20 aktuelle Artikel über MSD gefunden.
- MSD’s Phase IIb study of tulisokibart achieves primary endpoint
- MSD’s Phase IIb study of tulisokibart achieves primary endpoint
- MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
- MSD Korea launches subcutaneous Keytruda, cutting injection time to 1–2 minutes
- PAHO and MSD for Mothers sign agreement to reduce preventable maternal deaths in Guatemala and the Dominican Republic
- MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor
- Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
- MSD backs Ingenia as sole phase 3 TIE2 eye drug advances in Korea and US - CHOSUNBIZ
- MSD takes a $400m bite of SciBrunch's KRAS drug
- MSD Appoints Vidhya Sundaram As AVP, Global Technology Centers
- MSD, Daiichi pull filing for lung cancer candidate I-DXd
- MSD appoints Vidhya Sundaram as Associate Vice President, Global Technology Centers and Hyderabad Tech Center Lead
- Daiichi Sankyo, MSD withdraw cancer drug application
- MSD’s eye drug meets primary endpoint in trial
- Bio Farma and MSD Expand Strategic Partnership to Strengthen Local Vaccine Manufacturing Capabilities
- Wnt drug gives MSD first eye disease win after EyeBio deal
- MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests
- MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests
- MSD receives first shipment of Naltrexone for the treatment of alcohol addiction
- MSD reaffirms commitment to advancing women’s cancer care
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie MSD?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden